Skip to main content
. Author manuscript; available in PMC: 2022 Feb 24.
Published in final edited form as: Eur J Pharmacol. 2020 Jan 31;873:172981. doi: 10.1016/j.ejphar.2020.172981

Fig 2. Examination of NF-κB agonists in HEK293 cells.

Fig 2.

NF-κB signaling was examined in HEK293 cells that stably express a NF-κB luciferase reporter and were graphed versus a measurement of cell viability by a non-luciferase luminescence assay (CTG). Cells were treated with either antagonist or vehicle (DMSO) for 24 h. Graphs are representative of a single experiment where each condition was performed in triplicate. Each experiment was repeated 3 times. Mean ± S.E.M.